Vinay K. Pattalachinti

Vinay K. Pattalachinti

Auto-generated profile, based on publicly available information

Vinay K. Pattalachinti

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2025 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
VPVinay K. Pattalachinti
Vinay K. Pattalachinti
EHEmaan Haque
Emaan Haque
MYMahmoud Yousef
Mahmoud Yousef
AYAbdelrahman Yousef
Abdelrahman Yousef
SCSaikat Chowdhury
Saikat Chowdhury
JSJohn Paul Ying-Ching Shen
John Paul Ying-Ching Shen
Appendiceal Adenocarcinoma (AA) is a rare gastrointestinal cancer with no FDA-approved targeted therapies. Here, we retrospectively compare BRAF-mutant AA and colorectal cancer (CRC). BRAF mutation is rare in AA (3%). Unlike CRC, BRAFV600E AA is not associated with poor prognosis, female sex, microsatellite instability, mucinous histology, or poor differentiation. In both cancers, BRAFV600E but not atypical BRAF mutations are mutually exclusive with other Ras-activating mutations. BRAFV600E + EGFR inhibition shows efficacy in BRAFV600E AA (disease control rate = 80%, median progression-free survival = 7.1 months).

16 January 2024 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
VPVinay K. Pattalachinti
Vinay K. Pattalachinti
IIIchiaki Ito
Ichiaki Ito
SCSaikat Chowdhury
Saikat Chowdhury
AYAbdelrahman Yousef
Abdelrahman Yousef
YGYue Gu
Yue Gu
JSJohn Paul Ying-Ching Shen
John Paul Ying-Ching Shen
Appendiceal adenocarcinoma (AA) is unique from other gastrointestinal malignancies in that it almost exclusively metastasizes to the peritoneal cavity. However, few studies have investigated the molecular interaction of the peritoneal microenvironment and AA. Here, we use a multi-omics approach with orthotopic and flank-implanted patient-derived xenografts (PDX) to study the effect of the peritoneal microenvironment on AA. AA tumors implanted in the peritoneal microenvironment tended to grow faster and displayed greater nuclear expression of Ki-67 relative to the same tumors implanted in the flank. Comparing the tumor-specific transcriptome (excluding stromal transcription), the peritoneal microenvironment relatively upregulated genes related to proliferation, including MKI67 and EXO1. Peritoneal tumors were also enriched for proliferative gene sets, including E2F and Myc Targets. Proteomic studies found a 2.5-fold increased ratio of active-to-inactive phosphoforms of the YAP oncoprotein in peritoneal tumors, indicating downregulation of Hippo signaling. Implications: The peritoneal microenvironment promotes growth of appendiceal tumors and expression of proliferative pathways in PDXs.

2 April 2024
Verified
Other
Open access
VPVinay K. Pattalachinti
Vinay K. Pattalachinti
IIIchiaki Ito
Ichiaki Ito
SCSaikat Chowdhury
Saikat Chowdhury
AYAbdelrahman Yousef
Abdelrahman Yousef
YGYue Gu
Yue Gu
JSJohn Paul Ying-Ching Shen
John Paul Ying-Ching Shen
Figure S1: Individual chromogenic IHC figures for CDX2, Vimentin, and KU80 used to create the merged images shown in Figure 1a. Figure S2: Plots comparing tumor purity, which is the percent of total reads from a sample that were assigned to human reads, between models and implant sites. Figure S3: Volcano plot displaying differentially expressed genes (DEGs) from TM00351 peritoneal tumor microenvironment (TME) vs. TM00351 flank TME. Points were colored based on overlap with differentially expressed genes (DEGs) from comparing normal human visceral omentum against human subcutaneous adipose tissues. PDX unique DEGs are genes that were DEGs in the PDX TME comparison but were not differentially expressed in the human tissue comparison. Figure S4: Volcano plot displaying differentially expressed genes (DEGs) from PMCA-3 peritoneal tumor microenvironment (TME) vs. PMCA-3 flank TME. Points were colored based on overlap with differentially expressed genes (DEGs) from comparing normal human visceral omentum against human subcutaneous adipose tissues. PDX unique DEGs are genes that were DEGs in the PDX TME comparison but were not differentially expressed in the human tissue comparison. Figure S5: Volcano plot displaying differentially expressed genes (DEGs) from AAP16 peritoneal tumor microenvironment (TME) vs. AAP16 flank TME. Points were colored based on overlap with differentially expressed genes (DEGs) from comparing normal human visceral omentum against human subcutaneous adipose tissues. PDX unique DEGs are genes that were DEGs in the PDX TME comparison but were not differentially expressed in the human tissue comparison. Figure S6: Venn diagram showing overlap of high effect size differentially expressed genes (DEGs) (log2foldchange≥1 and padj≤0.05) that were relatively upregulated in the PDX peritoneal TME (vs. flank TME) and were relatively upregulated in the human visceral omentum (vs. human subcutaneous adipose tissue). Figure S7: TME Gene Set Enrichment analysis (GSEA) results for either all three models combined (top row) or each model separately (bottom three rows). Figure S8: Heatmaps using ward.D clustering on tumor transcriptome with the top 500 highest variance genes (left), tumor transcriptome with only differentially expressed genes (middle), and tumor microenvironment transcriptome with the top 500 highest variance genes (right). Z-transformed across rows. Each row represents a single gene. Figure S9: PCA plot using the human tumor transcriptomes subset to only the 223 differentially expressed genes identified by comparing expression in the peritoneal implant site to the flank implant site. Figure S10: Chromogenic Immunohistochemistry for KI67 (brown) split by implanted model (columns) and implant site (rows) alongside the same sample with H&E staining. Figure S11: Normalized counts for select genes specified in the leading-edge analysis that are relatively enriched by the peritoneal microenvironment split between genes upregulated in the goblet cell gene set (top) and the cell division gene sets (bottom). Figure S12: Normalized counts for select genes specified in the leading-edge analysis that are relatively enriched by the flank microenvironment. Figure S13: Volcano plots displaying differentially expressed genes (DEGs) from comparing intraperitoneal (IP) PDX tumor transcriptomes from TM00351 compared to flank PDX tumor transcriptomes from TM00351. Figure S14: Volcano plots displaying differentially expressed genes (DEGs) from comparing intraperitoneal (IP) PDX tumor transcriptomes from PMCA-3 compared to flank PDX tumor transcriptomes from PMCA-3. Figure S15: Volcano plots displaying differentially expressed genes (DEGs) from comparing intraperitoneal (IP) PDX tumor transcriptomes from PMCA-3 compared to flank PDX tumor transcriptomes from PMCA-3. Figure S16: Gene Set Enrichment Analysis (GSEA) conducted using differentially expressed genes (DEGs) from comparing TM00351 PDXs. Figure S17: Gene Set Enrichment Analysis (GSEA) conducted using differentially expressed genes (DEGs) from comparing PMCA-3 PDXs. Figure S18: Gene Set Enrichment Analysis (GSEA) conducted using differentially expressed genes (DEGs) from comparing AAP16 PDXs. Figure S19: Individual reverse phase protein array (RPPA) data for all of the identified proteins, z-transformed across rows separately for each model.

2 April 2024
Verified
Other
Open access
VPVinay K. Pattalachinti
Vinay K. Pattalachinti
IIIchiaki Ito
Ichiaki Ito
SCSaikat Chowdhury
Saikat Chowdhury
AYAbdelrahman Yousef
Abdelrahman Yousef
YGYue Gu
Yue Gu
JSJohn Paul Ying-Ching Shen
John Paul Ying-Ching Shen
Table S1: Tumor and PDX information (left) and the number of samples collected for each of the analyses (right). “Initial Implant Site” indicates where passages were run prior to the current experiments with the tumor. “Implant Site” indicates where the tumors were implanted to generate the data for this manuscript. Table S2: Table of antibodies used for immunohistochemistry (IHC). M, mouse; R, rabbit; Hu, human; Mk, monkey; NHP, non-human primates. Table S3: Differentially expressed genes from comparing the peritoneal PDX vs. flank PDX tumor transcriptomes. LFC>0 indicates relative upregulation in peritoneal PDXs.

2 April 2024
Verified
Other
Open access
VPVinay K. Pattalachinti
Vinay K. Pattalachinti
IIIchiaki Ito
Ichiaki Ito
SCSaikat Chowdhury
Saikat Chowdhury
AYAbdelrahman Yousef
Abdelrahman Yousef
YGYue Gu
Yue Gu
JSJohn Paul Ying-Ching Shen
John Paul Ying-Ching Shen
Appendiceal adenocarcinoma (AA) is unique from other gastrointestinal malignancies in that it almost exclusively metastasizes to the peritoneal cavity. However, few studies have investigated the molecular interaction of the peritoneal microenvironment and AA. Here, we use a multi-omics approach with orthotopic and flank-implanted patient-derived xenografts (PDX) to study the effect of the peritoneal microenvironment on AA. AA tumors implanted in the peritoneal microenvironment tended to grow faster and displayed greater nuclear expression of Ki-67 relative to the same tumors implanted in the flank. Comparing the tumor-specific transcriptome (excluding stromal transcription), the peritoneal microenvironment relatively upregulated genes related to proliferation, including MKI67 and EXO1. Peritoneal tumors were also enriched for proliferative gene sets, including E2F and Myc Targets. Proteomic studies found a 2.5-fold increased ratio of active-to-inactive phosphoforms of the YAP oncoprotein in peritoneal tumors, indicating downregulation of Hippo signaling.Implications:The peritoneal microenvironment promotes growth of appendiceal tumors and expression of proliferative pathways in PDXs.